Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.

Mov Disord. 2019 May;34(5):708-716. doi: 10.1002/mds.27565. Epub 2018 Dec 21.

PMID:
30575996
2.

Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa.

Hegerle N, Choi M, Sinclair J, Amin MN, Ollivault-Shiflett M, Curtis B, Laufer RS, Shridhar S, Brammer J, Toapanta FR, Holder IA, Pasetti MF, Lees A, Tennant SM, Cross AS, Simon R.

PLoS One. 2018 Sep 6;13(9):e0203143. doi: 10.1371/journal.pone.0203143. eCollection 2018.

3.

Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa.

Baliban SM, Yang M, Ramachandran G, Curtis B, Shridhar S, Laufer RS, Wang JY, Van Druff J, Higginson EE, Hegerle N, Varney KM, Galen JE, Tennant SM, Lees A, MacKerell AD Jr, Levine MM, Simon R.

PLoS Negl Trop Dis. 2017 Apr 7;11(4):e0005493. doi: 10.1371/journal.pntd.0005493. eCollection 2017 Apr.

4.

Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor.

Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS, Towfic F, Ator MA, Rubinstein E, Laifenfeld D, Orbach A, Shinar D, Marantz Y, Grossman I, Knappertz V, Hayden MR, Laufer R.

Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6145-E6152. Epub 2016 Sep 26.

5.

Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.

Li SW, Liu Y, Sampson PB, Patel NK, Forrest BT, Edwards L, Laufer R, Feher M, Ban F, Awrey DE, Hodgson R, Beletskaya I, Mao G, Mason JM, Wei X, Luo X, Kiarash R, Green E, Mak TW, Pan G, Pauls HW.

Bioorg Med Chem Lett. 2016 Oct 1;26(19):4625-4630. doi: 10.1016/j.bmcl.2016.08.063. Epub 2016 Aug 23.

PMID:
27592744
6.

Pridopidine activates neuroprotective pathways impaired in Huntington Disease.

Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, -Wagner AM, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, Zeskind B, Grossman I, Hayden MR.

Hum Mol Genet. 2016 Sep 15;25(18):3975-3987. doi: 10.1093/hmg/ddw238. Epub 2016 Jul 27.

7.

Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent.

Liu Y, Laufer R, Patel NK, Ng G, Sampson PB, Li SW, Lang Y, Feher M, Brokx R, Beletskaya I, Hodgson R, Plotnikova O, Awrey DE, Qiu W, Chirgadze NY, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Fletcher GC, Mak TW, Bray MR, Pauls HW.

ACS Med Chem Lett. 2016 May 6;7(7):671-5. doi: 10.1021/acsmedchemlett.5b00485. eCollection 2016 Jul 14.

8.

Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.

Laufer R, Li SW, Liu Y, Ng G, Lang Y, Feher M, Brokx R, Beletskaya I, Hodgson R, Mao G, Plotnikova O, Awrey DE, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Madeira B, Fletcher GC, Mak TW, Bray MR, Pauls HW.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3562-6. doi: 10.1016/j.bmcl.2016.06.021. Epub 2016 Jun 9.

PMID:
27335255
9.

Discovery of a Selective Series of Inhibitors of Plasmodium falciparum HDACs.

Ontoria JM, Paonessa G, Ponzi S, Ferrigno F, Nizi E, Biancofiore I, Malancona S, Graziani R, Roberts D, Willis P, Bresciani A, Gennari N, Cecchetti O, Monteagudo E, Orsale MV, Veneziano M, Di Marco A, Cellucci A, Laufer R, Altamura S, Summa V, Harper S.

ACS Med Chem Lett. 2016 Mar 5;7(5):454-9. doi: 10.1021/acsmedchemlett.5b00468. eCollection 2016 May 12.

10.

Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.

Grossman I, Knappertz V, Laifenfeld D, Ross C, Zeskind B, Kolitz S, Ladkani D, Hayardeny L, Loupe P, Laufer R, Hayden M.

Prog Neurobiol. 2017 May;152:114-130. doi: 10.1016/j.pneurobio.2016.02.001. Epub 2016 Mar 4. Review.

PMID:
26952809
11.

Simple method for purification of enterotoxigenic Escherichia coli fimbriae.

Curtis B, Grassel C, Laufer RS, Sears KT, Pasetti MF, Barry EM, Simon R.

Protein Expr Purif. 2016 Mar;119:130-5. doi: 10.1016/j.pep.2015.11.007. Epub 2015 Nov 12.

12.

Analysis of magnetic field plasma interactions using microparticles as probes.

Dropmann M, Laufer R, Herdrich G, Matthews LS, Hyde TW.

Phys Rev E Stat Nonlin Soft Matter Phys. 2015 Aug;92(2):023107. Epub 2015 Aug 26.

PMID:
26382535
13.

The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.

Liu Y, Lang Y, Patel NK, Ng G, Laufer R, Li SW, Edwards L, Forrest B, Sampson PB, Feher M, Ban F, Awrey DE, Beletskaya I, Mao G, Hodgson R, Plotnikova O, Qiu W, Chirgadze NY, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Madeira B, Fletcher GC, Mak TW, Bray MR, Pauls HW.

J Med Chem. 2015 Apr 23;58(8):3366-92. doi: 10.1021/jm501740a. Epub 2015 Apr 3.

PMID:
25763473
14.

The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.

Sampson PB, Liu Y, Forrest B, Cumming G, Li SW, Patel NK, Edwards L, Laufer R, Feher M, Ban F, Awrey DE, Mao G, Plotnikova O, Hodgson R, Beletskaya I, Mason JM, Luo X, Nadeem V, Wei X, Kiarash R, Madeira B, Huang P, Mak TW, Pan G, Pauls HW.

J Med Chem. 2015 Jan 8;58(1):147-69.

PMID:
25723005
15.

Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.

Laufer R, Ng G, Liu Y, Patel NK, Edwards LG, Lang Y, Li SW, Feher M, Awrey DE, Leung G, Beletskaya I, Plotnikova O, Mason JM, Hodgson R, Wei X, Mao G, Luo X, Huang P, Green E, Kiarash R, Lin DC, Harris-Brandts M, Ban F, Nadeem V, Mak TW, Pan GJ, Qiu W, Chirgadze NY, Pauls HW.

Bioorg Med Chem. 2014 Sep 1;22(17):4968-97. doi: 10.1016/j.bmc.2014.06.027. Epub 2014 Jun 23.

PMID:
25043312
16.

Inductively heated plasma waste treatment for energy recovery.

Herdrich G, Schmalzriedt S, Laufer R, Dropmann M, Gabrielli R.

Environ Technol. 2014 Aug;35(13-16):1611-7.

PMID:
24956751
17.

The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.

Sampson PB, Liu Y, Patel NK, Feher M, Forrest B, Li SW, Edwards L, Laufer R, Lang Y, Ban F, Awrey DE, Mao G, Plotnikova O, Leung G, Hodgson R, Mason JM, Wei X, Kiarash R, Green E, Qiu W, Chirgadze NY, Mak TW, Pan G, Pauls HW.

J Med Chem. 2015 Jan 8;58(1):130-46. doi: 10.1021/jm5005336. Epub 2014 Jun 24.

PMID:
24867403
18.

Consent versus scrutiny: restricting liberties in post-Bournewood Victoria.

Williams M, Chesterman J, Laufer R.

J Law Med. 2014 Mar;21(3):641-60.

PMID:
24804533
19.

HPLC determination of brain biogenic amines following treatment with bispyridinium aldoxime K203.

Hashemi F, Laufer R, Szegi P, Csomor V, Kalász H, Tekes K.

Acta Physiol Hung. 2014 Mar;101(1):40-6. doi: 10.1556/APhysiol.101.2014.1.5.

PMID:
24631794
20.

Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide.

Neuner P, Peier AM, Talamo F, Ingallinella P, Lahm A, Barbato G, Di Marco A, Desai K, Zytko K, Qian Y, Du X, Ricci D, Monteagudo E, Laufer R, Pocai A, Bianchi E, Marsh DJ, Pessi A.

J Pept Sci. 2014 Jan;20(1):7-19. doi: 10.1002/psc.2582. Epub 2013 Nov 13.

PMID:
24222478
21.

The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.

Laufer R, Forrest B, Li SW, Liu Y, Sampson P, Edwards L, Lang Y, Awrey DE, Mao G, Plotnikova O, Leung G, Hodgson R, Beletskaya I, Mason JM, Luo X, Wei X, Yao Y, Feher M, Ban F, Kiarash R, Green E, Mak TW, Pan G, Pauls HW.

J Med Chem. 2013 Aug 8;56(15):6069-87. doi: 10.1021/jm400380m. Epub 2013 Jul 26.

PMID:
23829549
22.

Medicinal chemistry of antimigraine drugs.

Tekes K, Szegi P, Hashemi F, Laufer R, Kalász H, Siddiq A, Ertsey C.

Curr Med Chem. 2013;20(26):3300-16. Review.

PMID:
23746273
23.

Nociceptinergic system as potential target in Parkinson's disease.

Tekes K, Tariq S, Adeghate E, Laufer R, Hashemi F, Siddiq A, Kalasz H.

Mini Rev Med Chem. 2013 Aug;13(10):1389-97. Review.

PMID:
23701656
24.

Effect of a single neonatal oxytocin treatment (hormonal imprinting) on the biogenic amine level of the adult rat brain: could oxytocin-induced labor cause pervasive developmental diseases?

Hashemi F, Tekes K, Laufer R, Szegi P, Tóthfalusi L, Csaba G.

Reprod Sci. 2013 Oct;20(10):1255-63. doi: 10.1177/1933719113483010. Epub 2013 Apr 2.

PMID:
23548412
25.

PEGylation of Neuromedin U yields a promising candidate for the treatment of obesity and diabetes.

Ingallinella P, Peier AM, Pocai A, Marco AD, Desai K, Zytko K, Qian Y, Du X, Cellucci A, Monteagudo E, Laufer R, Bianchi E, Marsh DJ, Pessi A.

Bioorg Med Chem. 2012 Aug 1;20(15):4751-9. doi: 10.1016/j.bmc.2012.06.003. Epub 2012 Jun 9.

PMID:
22771182
26.

Prodrugs and active metabolites among antidepressive compounds.

Tekes K, Hashemi F, Szegi P, Sotonyi P, Laufer R, Kalasz H.

Neuropsychopharmacol Hung. 2011 Jun;13(2):103-10. Review.

27.

Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase.

Narjes F, Crescenzi B, Ferrara M, Habermann J, Colarusso S, Ferreira Mdel R, Stansfield I, Mackay AC, Conte I, Ercolani C, Zaramella S, Palumbi MC, Meuleman P, Leroux-Roels G, Giuliano C, Fiore F, Di Marco S, Baiocco P, Koch U, Migliaccio G, Altamura S, Laufer R, De Francesco R, Rowley M.

J Med Chem. 2011 Jan 13;54(1):289-301. doi: 10.1021/jm1013105. Epub 2010 Dec 8.

PMID:
21141896
28.

Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR.

Jin M, Gokhale PC, Cooke A, Foreman K, Buck E, May EW, Feng L, Bittner MA, Kadalbajoo M, Landfair D, Siu KW, Stolz KM, Werner DS, Laufer RS, Li AH, Dong H, Steinig AG, Kleinberg A, Yao Y, Pachter JA, Wild R, Mulvihill MJ.

ACS Med Chem Lett. 2010 Aug 30;1(9):510-5. doi: 10.1021/ml100178g. eCollection 2010 Dec 9.

29.

Effect of perinatal stress on the biogenic amine neurotransmitter level of the adult rat's brain.

Tekes K, Szegi P, Laufer R, Hantos M, Csaba G.

Int J Dev Neurosci. 2011 Apr;29(2):171-5. doi: 10.1016/j.ijdevneu.2010.11.004. Epub 2010 Nov 30.

PMID:
21126566
30.

The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease.

Monteagudo E, Fonsi M, Chu X, Bleasby K, Evers R, Pucci V, Orsale MV, Cianetti S, Ferrara M, Harper S, Laufer R, Rowley M, Summa V.

Xenobiotica. 2010 Dec;40(12):826-39. doi: 10.3109/00498254.2010.519061. Epub 2010 Oct 7.

PMID:
20925584
31.

Pyridinium aldoxime analysis by HPLC: the method for studies on pharmacokinetics and stability.

Szegi P, Kalász H, Laufer R, Kuca K, Tekes K.

Anal Bioanal Chem. 2010 May;397(2):579-86. doi: 10.1007/s00216-010-3635-6. Epub 2010 Mar 28.

PMID:
20349225
32.

Enhancement of intestinal absorption of 2-methyl cytidine prodrugs.

Cianetti S, Cooper VB, Attenni B, Pucci V, Fiore F, Giuliano C, Laufer R, Gardelli C, Monteagudo E, Narjes F, Pearce GE, Rowley M.

Drug Deliv. 2010 May;17(4):214-22. doi: 10.3109/10717541003667814.

PMID:
20233089
33.

Activation of 5-HT3 receptors leads to altered responses 6 months after MDMA treatment.

Gyongyosi N, Balogh B, Katai Z, Molnar E, Laufer R, Tekes K, Bagdy G.

J Neural Transm (Vienna). 2010 Mar;117(3):285-92. doi: 10.1007/s00702-009-0357-z. Epub 2010 Jan 6.

PMID:
20052506
34.

Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.

Ontoria JM, Altamura S, Di Marco A, Ferrigno F, Laufer R, Muraglia E, Palumbi MC, Rowley M, Scarpelli R, Schultz-Fademrecht C, Serafini S, Steinkühler C, Jones P.

J Med Chem. 2009 Nov 12;52(21):6782-9. doi: 10.1021/jm900555u.

PMID:
19888759
35.

Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.

Gardelli C, Attenni B, Donghi M, Meppen M, Pacini B, Harper S, Di Marco A, Fiore F, Giuliano C, Pucci V, Laufer R, Gennari N, Marcucci I, Leone JF, Olsen DB, MacCoss M, Rowley M, Narjes F.

J Med Chem. 2009 Sep 10;52(17):5394-407. doi: 10.1021/jm900447q.

PMID:
19725579
36.

Monitoring by HPLC of chamomile flavonoids exposed to rat liver microsomal metabolism.

Petroianu G, Szoke E, Kalász H, Szegi P, Laufer R, Benko B, Darvas F, Tekes K.

Open Med Chem J. 2009 Jul 29;3:1-7. doi: 10.2174/1874104500903010001.

37.

Metabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fate.

Fonsi M, Fiore F, Jones P, Kinzel O, Laufer R, Rowley M, Monteagudo E.

Xenobiotica. 2009 Oct;39(10):722-37. doi: 10.1080/00498250903082279.

PMID:
19569735
38.

Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine.

Meppen M, Pacini B, Bazzo R, Koch U, Leone JF, Koeplinger KA, Rowley M, Altamura S, Di Marco A, Fiore F, Giuliano C, Gonzalez-Paz O, Laufer R, Pucci V, Narjes F, Gardelli C.

Eur J Med Chem. 2009 Sep;44(9):3765-70. doi: 10.1016/j.ejmech.2009.04.043. Epub 2009 May 8.

PMID:
19493593
39.

Synthesis and evaluation of novel phosphoramidate prodrugs of 2'-methyl cytidine as inhibitors of hepatitis C virus NS5B polymerase.

Donghi M, Attenni B, Gardelli C, Marco AD, Fiore F, Giuliano C, Laufer R, Leone JF, Pucci V, Rowley M, Narjes F.

Bioorg Med Chem Lett. 2009 Mar 1;19(5):1392-5. doi: 10.1016/j.bmcl.2009.01.035. Epub 2009 Jan 19.

PMID:
19181520
40.

Quantitative prediction of human clearance guiding the development of Raltegravir (MK-0518, isentress) and related HIV integrase inhibitors.

Laufer R, Paz OG, Di Marco A, Bonelli F, Monteagudo E, Summa V, Rowley M.

Drug Metab Dispos. 2009 Apr;37(4):873-83. doi: 10.1124/dmd.108.023804. Epub 2009 Jan 14.

PMID:
19144773
41.

Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.

Scarpelli R, Di Marco A, Ferrigno F, Laufer R, Marcucci I, Muraglia E, Ontoria JM, Rowley M, Serafini S, Steinkühler C, Jones P.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6078-82. doi: 10.1016/j.bmcl.2008.10.041. Epub 2008 Oct 12.

PMID:
18952417
42.

Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.

Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, Fiore F, Gardelli C, Gonzalez Paz O, Hazuda DJ, Jones P, Kinzel O, Laufer R, Monteagudo E, Muraglia E, Nizi E, Orvieto F, Pace P, Pescatore G, Scarpelli R, Stillmock K, Witmer MV, Rowley M.

J Med Chem. 2008 Sep 25;51(18):5843-55. doi: 10.1021/jm800245z.

PMID:
18763751
43.

Palladium-catalyzed direct heck arylation of dual pi-deficient/pi-excessive heteroaromatics. Synthesis of C-5 arylated imidazo[1,5-a]pyrazines.

Wang JX, McCubbin JA, Jin M, Laufer RS, Mao Y, Crew AP, Mulvihill MJ, Snieckus V.

Org Lett. 2008 Jul 17;10(14):2923-6. doi: 10.1021/ol800761r. Epub 2008 Jun 25.

PMID:
18576663
44.

Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors.

Muraglia E, Kinzel O, Gardelli C, Crescenzi B, Donghi M, Ferrara M, Nizi E, Orvieto F, Pescatore G, Laufer R, Gonzalez-Paz O, Di Marco A, Fiore F, Monteagudo E, Fonsi M, Felock PJ, Rowley M, Summa V.

J Med Chem. 2008 Feb 28;51(4):861-74. doi: 10.1021/jm701164t. Epub 2008 Jan 25.

PMID:
18217703
45.

A biogenetically-inspired synthesis of a ring-D model of kinamycin F: insights into the conformation of ring D.

Chen N, Carrière MB, Laufer RS, Taylor NJ, Dmitrienko GI.

Org Lett. 2008 Feb 7;10(3):381-4. doi: 10.1021/ol702650u. Epub 2008 Jan 10.

PMID:
18183994
46.

Studies of metabolism and disposition of potent human immunodeficiency virus (HIV) integrase inhibitors using 19F-NMR spectroscopy.

Monteagudo E, Pesci S, Taliani M, Fiore F, Petrocchi A, Nizi E, Rowley M, Laufer R, Summa V.

Xenobiotica. 2007 Sep;37(9):1000-12.

PMID:
17896326
47.

Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones.

Gardelli C, Nizi E, Muraglia E, Crescenzi B, Ferrara M, Orvieto F, Pace P, Pescatore G, Poma M, Ferreira Mdel R, Scarpelli R, Homnick CF, Ikemoto N, Alfieri A, Verdirame M, Bonelli F, Paz OG, Taliani M, Monteagudo E, Pesci S, Laufer R, Felock P, Stillmock KA, Hazuda D, Rowley M, Summa V.

J Med Chem. 2007 Oct 4;50(20):4953-75. Epub 2007 Sep 8.

PMID:
17824681
48.

Measurement of K-27, an oxime-type cholinesterase reactivator by high-performance liquid chromatography with electrochemical detection from different biological samples.

Gyenge M, Kalász H, Petroianu GA, Laufer R, Kuca K, Tekes K.

J Chromatogr A. 2007 Aug 17;1161(1-2):146-51. Epub 2007 Jun 16.

PMID:
17603065
49.

High-throughput radiometric CYP2C19 inhibition assay using tritiated (S)-mephenytoin.

Di Marco A, Cellucci A, Chaudhary A, Fonsi M, Laufer R.

Drug Metab Dispos. 2007 Oct;35(10):1737-43. Epub 2007 Jun 28.

PMID:
17600081
50.

Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors.

Pace P, Di Francesco ME, Gardelli C, Harper S, Muraglia E, Nizi E, Orvieto F, Petrocchi A, Poma M, Rowley M, Scarpelli R, Laufer R, Gonzalez Paz O, Monteagudo E, Bonelli F, Hazuda D, Stillmock KA, Summa V.

J Med Chem. 2007 May 3;50(9):2225-39. Epub 2007 Apr 12.

PMID:
17428043

Supplemental Content

Loading ...
Support Center